Biosimilars to treat inflammatory arthritis: The challenge of proving identity

Annals of the Rheumatic Diseases

Volumn 72, Issue 10, 2013, Pages 1589-1593

  Kay, Jonathan ^a   Smolen, Josef S ^b,c  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c HIETZING HOSPITAL   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; BIOSIMILAR AGENT; CT P 13; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; HERBACEOUS AGENT; INFLIXIMAB; METHOTREXATE; PLACEBO; PROTEIN; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANKYLOSING SPONDYLITIS; ANTIBODY BLOOD LEVEL; ANTIINFLAMMATORY ACTIVITY; BIOLOGICAL THERAPY; CLINICAL TRIAL (TOPIC); DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG INDICATION; DRUG POTENCY; DRUG PURITY; DRUG QUALITY; DRUG SAFETY; EDITORIAL; GLYCOSYLATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN PROCESSING; PROTEIN SYNTHESIS; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; STANDARD; TREATMENT DURATION; TREATMENT OUTCOME;

ANKYLOSING SPONDYLITIS; ANTI-TNF; PHARMACOKINETICS; RHEUMATOID ARTHRITIS; TREATMENT;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; METHOTREXATE; SPONDYLITIS, ANKYLOSING;

EID: 84883746643     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-203198     Document Type: Editorial

References (28)

1. Scheinberg MA, Kay J. The advent of biosimilar therapies in rheumatology-"O brave new world". Nat Rev Rheumatol 2012;8:430-6
2. Dorner T, Strand V, Castañeda-Hernández G, et al. The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis 2013;72:322-8
3. Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicenter, parallel-group, prospective study comparing the pharmacokinetics, safety and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 2013;72:1605-12
4. Yoo D-H, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when co-administered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013;72:1613-20
5. World Health Organization. Guidelines on evaluation of similar biotherapeutic products (SBPs). 2009. http://www.who.int/biologicals/areas/ biological-therapeutics/BIOTHERAPEUTICS-FOR-WEB- 22APRIL2010.pdf (accessed 6 May 2013)
6. Schiestl M, Stangler T, Torella C, et al. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 2011;29:310-12
7. United States Department of Health & Human Services, Food & Drug Administration (US). H. R. 3590-686. Patient Protection and Affordable Care Act. Title VII-Improving Access to Innovative Medical Therapies. Subtitle A-Biologics Price Competition and Innovation. Sec. 7002. Approval Pathway for Biosimilar Biological Products. 2010. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/ UCM216146.pdf (accessed 6 May 2013)
8. Committee for Medicinal Products for Human Use. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. 2006. http://www.ema.europa. eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003920. pdf (accessed 6 May 2013)
9. Committee for Medicinal Products for Human Use. Guideline on similar biological medicinal products containing monoclonal antibodies-non-clinical and clinical issues. 2012. http://www.ema.europa.eu/docs/en-GB/document-library/ Scientific-guideline/ 2012/06/WC500128686.pdf (accessed 6 May 2013)
10. Committee for Medicinal Products for Human Use. Concept paper on the revision of the guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. 2011. http://www. ema.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2011/10/WC500115611.pdf. (accessed 6 May 2013)
11. United States Department of Health & Human Services, Food & Drug Administration (US). Guidance for industry: Scientific considerations in demonstrating biosimilarity to a reference product, draft guidance. 2012. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM291128.pdf (accessed 6 May 2013)
12. United States Department of Health & Human Services, Food & Drug Administration (US). Guidance for industry: Non-inferiority clinical trials, draft guidance. 2010. http://www.fda.gov/downloads/ Drugs/ GuidanceComplianceRegulatoryInformation/ Guidances/UCM202140.pdf (accessed 6 May 2013)
13. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999;354:1932-9
14. St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004;50: 3432-43 (Pubitemid 39488667)
15. Zhang FC, Hou Y, Huang F. Infliximab versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a preliminary study from China. APLAR J Rheumatol 2006;9:127-30 (Pubitemid 44057326)
16. Abe T, Takeuchi T, Miyasaka N, et al. A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. J Rheumatol 2006;33:37-44 (Pubitemid 43054277)
17. Schiff M, Keiserman M, Codding C, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008;67:1096-103
18. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187-93 (Pubitemid 34304258)
19. van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52:582-91 (Pubitemid 40216323)
20. Park W, Jaworski J, Brzezicki J, et al. A randomised, double-blind, multicenter, parallel-group, phase 1 study comparing the pharmacokinetics, safety and efficacy of CT-P13 and infliximab in patients with active ankylosing spondylitis: 54 week results from the PLANETAS study [Abstract]. Ann Rheum Dis 2013;72(Suppl. 3):516
21. Yoo D-H, Racewicz A, Brzezicki J, et al. A phase 3 randomised controlled trial to compare CT-P13 with infliximab in patients with active rheumatoid arthritis: 54 week results from the PLANETRA study [Abstract]. Ann Rheum Dis 2013;72(Suppl. 3):73
22. Haraoui B, Smolen JS, Aletaha D, et al. Treating rheumatoid arthritis to target: multinational recommendations assessment questionnaire. Ann Rheum Dis 2011;70:1999-2002
23. Kay J. Biosimilars: a regulatory perspective from America. Arthritis Res Ther 2011;13:112
24. Remicade (infliximab) [Highlights of prescribing information]. Janssen Biotech, Inc. Last revised March 2013. 2013. http://www.accessdata.fda.gov/ drugsatfda-docs/label/2013/103772s5345lbl.pdf (accessed 6 May 2013)
25. GaBI Online-Generics and Biosimilars Initiative. Biosimilar monoclonal antibody approved in Korea. 2012. http://www.gabionline.net/Biosimilars/News/ Biosimilar-monoclonal-antibody-approved-in-Korea (accessed 6 May 2013)
26. Committee for Medicinal Products for Human Use. Summary of positive opinion for Remsima. 2013. http://www.ema.europa.eu/docs/en-GB/document-library/ Summary-of-opinion-Initial-authorisation/human/002576/WC500144832.pdf (accessed 4 Jul 2013)
27. GaBI Online-Generics and Biosimilars Initiative. US $67 billion worth of biosimilar patents expiring before 2020. 2012. http://www.gabionline. net/Biosimilars/ General/US-67-billion-worth-of-biosimilar-patentsexpiring- before-2020 (accessed 6 May 2013)
28. Jack A. Regulators pave way for 'biosimilar' drugs. Financial Times. 29 June 2013/30 June; 13.